Figure 6.
Fe3O4 MNP and AT combination suppressed NSCLC in a p53-dependent manner.
Notes: (A) A549 and H1975 were treated with AT-MNPs for different times (0, 6, 12, 24, and 48 hours). Upper row: p53 protein in whole-cell lysates was determined by specific antibody; lower row: quantification of p53 following immunoblot analysis. (B) A549 and H1975 cells were treated with MNPs at the concentrations indicated (0, 5, 10, 20, and 40 μg/mL) in the absence of AT for 24 hours. Upper row: Western blot was used to determine p53 protein expression levels; lower row: quantification of p53 levels. (C) A549 and H1975 cells were treated with AT at the concentrations indicated (0, 5, 10, 20, and 30 μM) in the absence of MNPs for 24 hours. Upper row: immunoblot was used to determine p53 protein expression levels; lower row: quantification of p53 levels. (D, E) Upper row: Western blot was carried out to calculate FADD and p53 protein levels in (D) A549 and (E) H1975 cells after AT-MNP combination treatment in the presence or absence of p53 inhibitor PFTα with specific antibodies; lower row: quantification of protein levels. RT-qPCR analysis was used to detect DR4, DR5, and TRAIL mRNA levels in (F) A549 and (G) H1975 cells after cotreatment with AT-MNPs with or without PFTα. Values are expressed as means ± standard error of mean. *P<0.05, **P<0.01, and ***P<0.001 vs Con group; ##P<0.01; ###P<0.001. Analysis of variance and Dunnett’s analysis were included to compare the averages of multiple groups.
Abbreviations: MNPs, magnetic nanoparticles; AT, actein; NSCLC, non-small-cell lung cancer; mRNA, messenger RNA; PFT, pifithrin; RT-qPCR, real-time quantitative polymerase chain reaction; Con, control.